Older age, presence of multiple comorbidities, and longer length of hospital stay, rather than difference in glycaemic control, were associated with an increased risk of 1-year death following admission with severe hypoglycaemia in patients with diabetes, according to a Singapore study.
Adding continuous glucose monitoring (CGM) to conventional finger-prick test during pregnancy increases the time spent in the recommended glycaemic target range and improves neonatal health outcomes in patients with type 1 diabetes (T1D) compared with traditional test alone, according to the CONCEPTT* study presented at EASD 2017.
Dapagliflozin improves glycaemic control with sustained weight loss without an increased risk of diabetic ketoacidosis (DKA) in patients with type 1 diabetes (T1D) who are inadequately controlled with insulin, according to the DEPICT-1* study.
Once-weekly doses of the glucagon-like peptide-1 receptor agonist exenatide plus insulin glargine improved glucose control and weight loss in patients whose type 2 diabetes (T2D) was uncontrolled on basal insulin and metformin, according to findings from the DURATION-7* trial.
The novel, G-protein coupled receptor 119 (GPR119) agonist DS-8500a demonstrated dose-dependent glucose-lowering effects and favourable improvements in lipid parameters that extended up to 12 weeks in Japanese patients with type 2 diabetes mellitus (T2D), according to data presented at EASD 2017.
Individuals with type 2 diabetes (T2D) who were hospitalized with nonalcoholic fatty liver disease (NAFLD) had an elevated risk of cardiovascular disease (CVD), and death due to CVD, hepatocellular cancer, and other causes, according to a study presented at EASD 2017.
The incidence of cardiovascular (CV) events at 5 years was similar when adding sulphonylureas or pioglitazone to metformin in patients with type 2 diabetes (T2D) inadequately controlled with metformin alone, according to a head-to-head comparison in the TOSCA.IT* trial.
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng,
10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
A single infusion of the monoclonal antibody rituximab temporarily delays the clinical onset of rheumatoid arthritis (RA) through B-cell depletion, underpinning the preventive potential of rituximab in RA development especially in high-risk individuals, according to the PRAIRI* study.
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).